P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
- Resource Type
- Abstract
- Source
- In
Annals of Oncology July 2021 32 Supplement 3:S137-S137 - Subject
- Language
- ISSN
- 0923-7534